Methods for modulating cell-to-cell adhesion using an agonist of C1INH-type protein activity
AssigneeThe CBR Institute for Biomedical Research, Inc.
InventorsAlvin Davis, Shenghe Cai
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe CBR Institute for Biomedical Research, Inc.
InventorsAlvin Davis, Shenghe Cai
Estimating the term…
The present invention is based, at least in part, on the discovery that plasma C1INH contains a sialyl Lewisx related moiety on its N-glycan and is capable of binding selectin molecules. The invention provides methods for modulating cell-to-cell adhesion or cell migration comprising contacting a cell with a C1INH-type protein or fragment thereof or a nucleic acid encoding a C1INH-type protein or fragment thereof, such that cell-to-cell adhesion is modulated. The invention also provides methods for treating or preventing cell adhesion related disorders in a subject comprising administering to the subject an effective amount of a C1INH-type protein or fragment thereof or a nucleic acid encoding a C1INH-type protein or fragment thereof.
A method for modulating cell-to-cell adhesion comprising contacting a cell with an agonist of C1INH-type protein activity, such that cell-to-cell adhesion is modulated.
A method for modulating cell-to-cell adhesion, comprising contacting soluble P-selectin with a C1INH-type protein, such that said cell-to-cell adhesion is modulated.
A method for treating or preventing a cell adhesion related disorder in a subject, comprising administering to said subject an effective amount of a composition comprising an agonist of C1INH-type protein activity such that said cell adhesion related disorder is treated.
A method for identifying a compound capable of modulating cell to cell adhesion comprising assaying the ability of the compound to modulate C1INH-type protein activity, thereby identifying a compound capable of modulating cell to cell adhesion.
Dependencies are inferred from the claim text.